Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Cefalexin monohydrate; Kanamycin monosulphate
Boehringer Ingelheim Vetmedica GmbH
QJ51RD01
Cefalexin monohydrate; Kanamycin monosulphate
200 mg/100,000 IU per syringe
Intramammary suspension
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle
cefalexin, combinations with other antibacterials
Antibacterial
Authorised
2007-10-26
Health Products Regulatory Authority 25 May 2018 CRN000YHZ Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ubrolexin intramammary suspension for lactating dairy cows 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 g (12 ml) intramammary syringe contains: ACTIVE SUBSTANCES: Cefalexin (as monohydrate): 200 mg Kanamycin (as monosulphate): 100,000 I.U. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Intramammary suspension.Off-white, oily paste. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (lactating dairy cows). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of clinical mastitis in lactating dairy cows for bacteria susceptible to the combination of cefalexin and kanamycin such as _Staphylococcus aureus _(see section 5.1), _Streptococcus dysgalactiae_, _Streptococcus uberis _and _Escherichia coli_. 4.3 CONTRAINDICATIONS Do not use in lactating dairy cows with a known hypersensitivity to cefalexin and/or kanamycin. Do not use in non-lactating cattle. Do not use in the case of known resistance of cefalexin and/or kanamycin. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Health Products Regulatory Authority 25 May 2018 CRN000YHZ Page 2 of 6 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Recommendations for prudent use The product should be used for treatment of clinical mastitis only. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional and farm level) epidemiological information about susceptibility of the target bacteria as well as by taking into account official national antimicrobial policies. Inappropriate use of the product may increase the prevalence of bacteria resistant to cefalexin and kanamycin and may decrease the effectiveness of treatment with other cephalosporins or aminoglycosides due to the potential for cross-resistance. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMIN Read the complete document